Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

95/433 Matches for
“Public health”

“Public health” Clear all
  1. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 100

    …easy-to-use reference for public health authorities in Europe and elsewhere…

    FibroTest HBV HCV

  2. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 100

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  3. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 99

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  4. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 99

    Although most hepatitis C virus (HCV) infections are acquired by injection drug…

    FibroTest

  5. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 98

    Hepatitis C virus (HCV) infection is a major cause of chronic liver…

    FibroTest HCV

  6. American Association for the Study of the Liver

    Match 98

    FibroTest HCV

  7. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 97

    FibroTest Alcohol HBV HCV +1

  8. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 97

    FibroTest HBV

  9. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 96

    FibroTest Alcohol

  10. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 96

    …from the First Israeli National Health Survey, without excessive alcohol consumption or…

    SteatoTest Metabolic

  11. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 95

    …Index to Nursing and Allied Health Literature (from 1982 to January 2010…

    FibroTest Alcohol

  12. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 95

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  13. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.

    Mossong J et al. · Bull Soc Sci Med Grand Duche Luxemb · 2011 Match 94

    ### Objective The aim of our study was to assess the diagnostic performance…

    FibroTest HCV

  14. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 94

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  15. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 93

    ActiTest FibroTest HCV

  16. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 93

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  17. Non-invasive evaluation of liver fibrosis in chronic hepatitis C.

    Trifan A et al. · Rev Med Chir Soc Med Nat Iasi · 2012 Match 92

    Chronic hepatitis C (CHC) is a major public health concern, with around…

    FibroTest HCV

  18. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 92

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  19. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Match 91

    ### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…

    ActiTest FibroTest HBV HCV

  20. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 90

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  21. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.

    Carlson JJ et al. · J Gastroenterol Hepatol · 2009 Match 90

    …and costs, evaluated from the health-care payer perspective. ### Results The testing…

    FibroTest

  22. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 89

    …Recently, the guidelines produced by the World Health Organization have suggested that…

    FibroTest HCV

  23. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 89

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  24. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 88

    FibroTest Alcohol HBV HCV +1

  25. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 88

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  26. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 87

    ### Introduction The purpose of this clinical trial was to determine in routine…

    ActiTest FibroTest HCV

  27. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 87

    FibroTest HCV

  28. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 86

    FibroTest Other

  29. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 86

    FibroTest HCV

  30. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 85

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  31. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 85

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  32. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 84

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  33. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 84

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  34. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 83

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  35. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 83

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  36. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

    Rossi E et al. · Clin Chem · 2003 Match 82

    ### Background Determining the stage of fibrosis by liver biopsy is important in…

    FibroTest HCV

  37. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 82

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  38. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 81

    ActiTest AshTest FibroTest NashTest +6

  39. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 80

    FibroTest HCV

  40. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 80

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  41. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 79

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  42. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 79

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  43. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 78

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  44. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 78

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  45. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 77

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  46. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006 Match 77

    ### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…

    FibroTest Alcohol HBV HCV

  47. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 76

    FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…

    ActiTest FibroTest HCV

  48. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 76

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  49. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

    Lewin M et al. · Hepatology · 2007 Match 75

    ### Unlabelled Liver biopsy is the gold standard for assessing fibrosis but has…

    FibroTest HCV

  50. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 75

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  51. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 74

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  52. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 74

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  53. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 73

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  54. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 73

    ### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…

    FibroTest HBV HCV Other

  55. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 72

    ### Background & Aims Real-time shear wave elastography (SWE) is a new two…

    FibroTest Alcohol HBV HCV +3

  56. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 72

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  57. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 71

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  58. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 70

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  59. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 70

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  60. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 69

    ActiTest FibroTest HBV

  61. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 69

    …375) of the Israeli National Health and Nutrition Survey. Exclusion criteria were…

    SteatoTest Metabolic

  62. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 68

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  63. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021 Match 68

    ### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…

    FibroTest HBV

  64. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 67

    ### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…

    FibroTest SteatoTest Alcohol

  65. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 67

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  66. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 66

    The aim was to assess the utility of FibroTest-ActiTest (FT-AT…

    ActiTest FibroTest HBV

  67. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 66

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  68. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 65

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  69. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

    Cacoub P et al. · J Hepatol · 2008 Match 65

    ### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…

    FibroTest HCV HIV

  70. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 64

    ActiTest FibroTest HBV

  71. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 64

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  72. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 63

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  73. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 63

    ### Background & Aims There is controversy about the performance of noninvasive tests such…

    FibroTest Alcohol HBV HCV +3

  74. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 62

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  75. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 62

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  76. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 61

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  77. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 60

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  78. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 60

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  79. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 59

    …To maximize the health benefits of SVR, counseling patients on best means…

    FibroTest HCV

  80. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 59

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  81. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 58

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  82. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 58

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  83. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 57

    …line estimate of liver fibrosis. Health authorities in some countries have already…

    FibroTest Alcohol HBV HCV +3

  84. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 57

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  85. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 56

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  86. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 56

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  87. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 55

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  88. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 55

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  89. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 54

    …Due to the evidence-based data, health authorities in some countries have…

    ActiTest FibroTest SteatoTest Alcohol +5

  90. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 54

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  91. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 53

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  92. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 53

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  93. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 52

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  94. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 52

    ActiTest FibroTest HCV

  95. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.